Skip to Content
Watertown Bio
Home
Newsletter
Community Overview
Organization Gallery
Therapeutic Pipeline Overview
Industry Reports
About
Contact
Support Us
(0)
Cart (0)
Support Watertown Bio
Watertown Bio
Home
Newsletter
Community Overview
Organization Gallery
Therapeutic Pipeline Overview
Industry Reports
About
Contact
Support Us
(0)
Cart (0)
Support Watertown Bio
Home
Newsletter
Folder: Life Science Community Info
Back
Community Overview
Organization Gallery
Therapeutic Pipeline Overview
Industry Reports
Folder: About Us
Back
About
Contact
Support Us
Support Watertown Bio
Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market
News Roundup Sam Ghilardi 5/26/26 News Roundup Sam Ghilardi 5/26/26

Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market

Plus the initial dosing of Enanta and Avencell's Clinical Trials

Read More
Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation
News Roundup Sam Ghilardi 3/31/26 News Roundup Sam Ghilardi 3/31/26

Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation

Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates

Read More
News Roundup Sam Ghilardi 11/18/25 News Roundup Sam Ghilardi 11/18/25

Labshares Expanding to Watertown

Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more

Read More

Watertown Bio

Contact

info@watertown.bio